Following its surprise effect on cancer in the CANTOS study, Novartis AG is set to take its anti-IL1β monoclonal canakinumab (ACZ885) on a path recently travelled so successfully by AstraZeneca PLC's Imfinzi with a Phase III study planned in the earlier stage lung cancer.
It gave an outline of its confirmatory Phase III study plans during its recent third quarter financial results presentation and...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)